Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

Phoenix—Former U.S. Navy pilot Matt Bellina lives with

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
condoe3 Member Profile
Followed By 1
Posts 629
Boards Moderated 0
Alias Born 02/02/12
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2019 5:03:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/11/2019 5:03:07 PM
BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting GlobeNewswire Inc. - 5/31/2019 1:00:00 AM
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study GlobeNewswire Inc. - 5/30/2019 1:00:00 AM
BrainStorm Senior Management to Present at BIO 2019 GlobeNewswire Inc. - 5/28/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/13/2019 8:01:41 AM
BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London GlobeNewswire Inc. - 5/13/2019 1:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:03:29 PM
BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update GlobeNewswire Inc. - 5/10/2019 5:00:00 PM
BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases GlobeNewswire Inc. - 4/30/2019 4:00:00 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/1/2019 3:35:52 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/29/2019 5:08:02 PM
Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting GlobeNewswire Inc. - 3/28/2019 4:30:00 AM
BrainStorm Announces Grant of an additional New European Patent for NurOwn® GlobeNewswire Inc. - 3/26/2019 6:30:00 AM
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS GlobeNewswire Inc. - 3/14/2019 1:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/12/2019 6:13:38 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/8/2019 5:05:02 PM
BrainStorm to Host Business Update Conference Call GlobeNewswire Inc. - 3/7/2019 4:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/22/2019 5:03:13 PM
BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study GlobeNewswire Inc. - 2/22/2019 7:30:00 AM
BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland GlobeNewswire Inc. - 2/21/2019 6:00:00 AM
BrainStorm Issues a Statement to Patients and Shareholders GlobeNewswire Inc. - 2/19/2019 8:06:49 AM
BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposiu... GlobeNewswire Inc. - 2/4/2019 8:22:51 AM
BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida GlobeNewswire Inc. - 1/25/2019 7:15:00 AM
BrainStorm Granted Additional Patent for NurOwn® in Israel GlobeNewswire Inc. - 1/22/2019 8:40:00 AM
condoe3   Tuesday, 02/05/19 11:33:38 PM
Re: None
Post # of 2527 
Phoenix—Former U.S. Navy pilot Matt Bellina lives with amyotrophic lateral sclerosis (ALS), and since the time of his diagnosis in 2014, he had exhausted the treatment options available to him. But he successfully fought for the right to try investigational treatments so that he and others in his situation could have hope. Today, the Goldwater Institute is pleased to learn that Bellina is undergoing treatment for ALS under the federal Right to Try law. The treatment, NurOwn, is currently in Phase 3 trials.

In a Facebook post today, Bellina announced that he began the investigational treatment one month ago. Since his treatment began, he has experienced “increased core strength and coordination,” which now allows him to pull himself up to standing. Additionally, he has seen “subjective improvement” in his speech and swallowing. “I have been given a gift,” Bellina wrote of his treatment. “Because this is an investigational therapy we don’t know what tomorrow will bring but for now we are feeling incredibly blessed,” he continued.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist